Hemogenyx Pharmaceuticals Plc (HEMO.L)
- Previous Close
178.75 - Open
183.73 - Bid 177.00 x --
- Ask 179.00 x --
- Day's Range
177.00 - 183.73 - 52 Week Range
160.00 - 1,200.00 - Volume
10,409 - Avg. Volume
43,182 - Market Cap (intraday)
7.419M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
hemogenyx.comRecent News: HEMO.L
View MorePerformance Overview: HEMO.L
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEMO.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEMO.L
View MoreValuation Measures
Market Cap
7.32M
Enterprise Value
9.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.15%
Return on Equity (ttm)
-309.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.62M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
159.26k
Total Debt/Equity (mrq)
307.33%
Levered Free Cash Flow (ttm)
-1.96M